10 Participants Needed

NK Cells + N-803 for Kidney and Bladder Cancer

Recruiting at 2 trial locations
WX
Overseen ByWenxin Xu, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you must stop taking your current medications. However, you cannot have had anti-tumor chemotherapy or investigational agents within 2 weeks prior to enrollment, or immunotherapy within 4 weeks prior. Also, you cannot be on systemic corticosteroid therapy at a dose of 10 mg or more of prednisone (or equivalent) for at least 2 weeks before enrolling.

What data supports the effectiveness of the treatment NK Cells + N-803 for Kidney and Bladder Cancer?

Research shows that cytokine-induced memory-like natural killer (CIML NK) cells, which are part of this treatment, have demonstrated enhanced anticancer functionality and promising clinical activity in early trials. Additionally, similar treatments using cytokine-induced killer (CIK) cells have shown effectiveness in treating renal cell carcinoma, with some patients experiencing complete or partial responses.12345

Is the NK Cells + N-803 treatment safe for humans?

Early clinical trials and preclinical studies suggest that cytokine-induced memory-like (CIML) NK cells, which are part of the NK Cells + N-803 treatment, are generally safe for humans, with promising results in treating certain cancers like acute myeloid leukemia.45678

What makes the NK Cells + N-803 treatment unique for kidney and bladder cancer?

This treatment is unique because it uses cytokine-induced memory-like (CIML) natural killer (NK) cells, which are enhanced by a combination of cytokines (IL-12, IL-15, and IL-18) to improve their longevity and anticancer functionality. This approach aims to overcome the limitations of traditional NK cell therapies by boosting their ability to remember and respond more effectively to cancer cells.345910

What is the purpose of this trial?

The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood that is collected and bathed in special proteins to help identify and treat curtained advanced cancers, combined with low dose IL-2, which is a cytokine that activates immune cells, in advanced clear cell renal cell carcinoma and urothelial carcinoma.Names of the study therapies involved in this study are/is:* CIML NK cell therapy (a NK cell therapy)* IL-2 (a type of cytokine)

Research Team

WX

Wenxin Xu, MD

Principal Investigator

Dana-Farber Cancer Institute

Eligibility Criteria

This trial is for adults with advanced renal cell carcinoma or urothelial carcinoma. Participants must have measurable disease and be able to provide a sample of their tumor tissue. They should not have had any other cancer treatments like chemotherapy, radiation, or surgery within the last 4 weeks.

Inclusion Criteria

I am fully active and can carry on all my pre-disease activities without restriction.
Ability to understand and the willingness to sign a written informed consent document.
Willing to provide blood and tissue from diagnostic biopsy.
See 7 more

Exclusion Criteria

I have lasting side effects from previous treatments, but they are not severe.
Prior recipients of organ transplantation including allogeneic stem cell transplantation.
I have heart problems that affect my daily life.
See 14 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks
1 visit (in-person)

Leukapheresis and Chemotherapy

Collection of NK cells through leukapheresis and administration of lymphodepleting chemotherapy

1 week
Multiple visits (in-person)

Treatment

Administration of CIML NK Cell Therapy and low dose IL-2

4 weeks
Daily visits for infusion and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Every 3 months in-clinic, with CT, MRI, or PET scan; every 4 months follow-up in-clinic, by phone, or remotely

Treatment Details

Interventions

  • Cytokine Induced Memory-like Natural Killer (CIML NK) Cells
  • N-803
Trial Overview The study tests CIML NK cell therapy combined with N-803 in patients. CIML NK cells are immune cells treated to target cancer better, while N-803 boosts these cells' activity. The aim is to see if this combo is safe and how well it works against kidney and bladder cancers.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Dose Level 0: CIML NK + low dose IL-2Experimental Treatment2 Interventions
Participants will be enrolled in a staggered fashion into a 3+3 dose de-escalation design per protocol to establish a maximum tolerated dose (MTD) of CIML NK Cells. Dose will start at Dose Level 0. * Baseline visit. * Day -7: Apheresis for autologous NK cell collection. * Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol. * Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital. * Days 1 through 8: Low dose IL-2 every other day * Day 28 and then ever 2-3 months: CT/MRI/PET * In-clinic visit every 3 months with CT, MRI, or PET scan. * End of Treatment: in-clinic visit * Follow Up: every 4 months in-clinic, by telephone, or remotely. * If 2 or more out of 5 participants experience dose-limiting toxicities (DLTs), subsequent dose will be de-escalated to Dose Level -1.
Group II: Dose Level -1: CIML NK + low dose IL-2Experimental Treatment2 Interventions
Participants will complete: * Baseline visit. * Day -7: Apheresis for autologous NK cell collection. * Days -6 through -2: Predetermined dose of standard of care lymphodepleting chemotherapy per protocol. * Days 0: Predetermined dose of CIML NK Cell Therapy infusion 1x daily administered in-clinic or hospital. * Days 1 to 8: low dose IL-2 every other day * Day 28 and then ever 2-3 months: CT/MRI/PET * In-clinic visit every 3 months with CT, MRI, or PET scan. * End of Treatment: in-clinic visit * Follow Up: every 4 months in-clinic, by phone, or remotely. * If 1 or less DLTs are observed, this will be the maximum tolerated dose. If 2 or more DLTs are observed, accrual will stop.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials
1,128
Recruited
382,000+

Kidney Cancer Association

Collaborator

Trials
1
Recruited
5+

ImmunityBio, Inc.

Industry Sponsor

Trials
75
Recruited
5,000+

Richard Adcock

ImmunityBio, Inc.

Chief Executive Officer since 2024

Information not available

Dr. Patrick Soon-Shiong

ImmunityBio, Inc.

Chief Medical Officer since 2021

MD

Findings from Research

Cytokine-Induced Killer (CIK) cells are a promising option for cancer therapy due to their ability to be easily expanded and activated without needing specific antigens, allowing them to target tumor cells effectively in an HLA-independent manner.
CIK cells show reduced alloreactivity compared to traditional T cells, making them safer for use in patients, with only mild graft-versus-host disease (GVHD) reported in a few cases, and their effectiveness can be enhanced using techniques like chimeric antigen receptors and immune checkpoint inhibitors.
Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.Cappuzzello, E., Sommaggio, R., Zanovello, P., et al.[2022]
Autologous cytokine-induced killer (CIK) cell immunotherapy significantly improved the immune response in colorectal cancer patients, with notable increases in key immune cell subsets after 14 days of treatment.
Patients receiving CIK cell therapy showed longer progression-free survival (25.8 months) and overall survival (41.3 months) compared to the control group, indicating that this therapy can effectively enhance survival outcomes when combined with chemotherapy.
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.Zhang, J., Zhu, L., Zhang, Q., et al.[2020]
Cytokine-induced killer (CIK) cell therapy was administered to 16 patients with metastatic renal cell carcinoma (mRCC), showing minimal toxicity and no immediate adverse reactions, indicating a safe treatment option.
The therapy resulted in significant immunological responses, with 3 patients achieving complete response and 1 patient achieving partial response, suggesting that CIK cell immunotherapy is effective in enhancing the immune function against mRCC.
Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.Su, X., Zhang, L., Jin, L., et al.[2010]

References

Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells. [2022]
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study. [2020]
Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. [2010]
Cytokine-induced memory-like natural killer cells for cancer immunotherapy. [2023]
Human Cytokine-Induced Memory-Like Natural Killer Cells. [2020]
Enhanced expression of natural cytotoxicity receptors on cytokine-induced memory-like natural killer cells correlates with effector function. [2023]
Innovative Clinical Perspectives for CIK Cells in Cancer Patients. [2022]
Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications. [2022]
The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security